Key result
AZD8165, a clinical candidate from a novel series of neutral thrombin inhibitors, was developed using a selection process based on docking experiments and property predictions.
Key points are not available for this paper at this time.
Extends docking-based selection to neutral thrombin inhibitors; leaves open clinical translation in cardiovascular patients.
A novel series of neutral thrombin inhibitors has been developed using a selection process based on docking experiments and property calculations and predictions.
No takes yet. Share an insight, caveat, or question.
Abrahamsson et al. (2015) studied this question. AZD8165, a clinical candidate from a novel series of neutral thrombin inhibitors, was developed using a selection process based on docking experiments and property predictions.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: